An observational study in Sleep Apnea, Obstructive Sleep Apnea and Pulmonary Hypertension, sponsored by Chinese Pulmonary Vascular Disease Research Group. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Chinese Pulmonary Vascular Disease Research Group · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies in Sleep Apnea, Obstructive with a site in China — 48 open to participants now, 50 under way, 10 of them phase 3. Sleep Apnea, Obstructive · China.
Among the 108 studies in Sleep Apnea, Obstructive with a site in China, this one is the 14th largest by planned enrollment of the 47 observational ones that give a count, is one of 5 that started in 2020, is one of 47 observational ones, reaches primary completion later than 42 of the 49 other live ones, and was the 55th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →48 of the 108 studies in Sleep Apnea, Obstructive with a site in China are open now. Recruiting first, the newest first:
Chinese Pulmonary Vascular Disease Research Group · Sites in China
Ages 18+
Peking University First Hospital · Sites in China
Ages 18–65 · Healthy volunteers
Beijing Anzhen Hospital · Sites in China
Ages 18–75
Novo Nordisk A/S · Sites in China, United States, Australia and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in China, United States, Australia and 7 more countries
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 480 is above the median of 105 across 668 observational studies indexed under Sleep Apnea, Obstructive.
Median enrollment 140 across the 60 interventional studies, 200 across the 47 observational. Of the 40 that completed or were terminated, 4 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 108 have an industry lead sponsor. The 10 most frequent:
Chinese Pulmonary Vascular Disease Research Group is the lead sponsor of 17 studies on the registry; 11 are open to participants now.
Chinese Pulmonary Vascular Disease Research Group has 4 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
11 of the studies in Sleep Apnea, Obstructive with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06974851Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity | 2026-12 |
| NCT07493057Phase 3Gan & Lee Pharmaceuticals.Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy | 2027-11-14 |
| NCT05735444Shanghai Jiao Tong University School of MedicineProspective National Multi-center Registry of Obstructive Sleep Apnea Syndrome in Hypertensive Patients in China | 2026-12 |
| NCT07307560Zhejiang UniversityHigh-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients | 2026-12-01 |
| NCT07908160Peking University First HospitalDevelopment and Clinical Validation of Artificial Intelligence Algorithms for Sleep Staging and Obstructive Sleep Apnea Screening Based on a Large-Scale Model Trained on Multimodal Physiological Signals From Diverse Populations | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 108 studies in Sleep Apnea, Obstructive with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators propose a prospective, observational study to determine the impact of OSA and associated physiological parameters on clinical outcomes in patients with pulmonary hypertension. The prevalence, phenotypes, and predictors of OSA in the setting of pulmonary hypertension will also be investigated. Adult patients diagnosed with pulmonary hypertension by right heart catheterization are eligible. Recruited patients will undergo an overnight cardiorespiratory study using a Level III portable device before hospital discharge. The cardiorespiratory tracings during sleep will be analyzed and audited by a certified sleep physician. The patients will be divided into two groups based on the apnea-hypopnea index (AHI): OSA (AHI ≥ 5) and non-OSA (AHI\<5) groups. Hypoxemic parameters such as time percentage spent with oxygen saturation below 90% and nadir oxygen saturation were all collected. Baseline clinical characteristics, such as the Epworth sleepiness scales, were also obtained. The primary endpoint of this study was clinical worsening (CW), defined as the composite event of a reduction in exercise capacity, worsening in World Health Organization functional class, non-elective hospitalization for pulmonary hypertension, or all-cause mortality. Secondary endpoints include individual outcomes of clinical worsening and all-cause mortality.
Obstructive sleep apnea (OSA) is a highly prevalent sleep-breathing disorder that affects over 1 billion adults worldwide, resulting in a substantial economic and medical burden. Multiple cardiovascular comorbidities and mortality are associated with OSA due to intermittent hypoxemia, intrathoracic pressure swings, sympathetic activation, endothelial dysfunction, and systemic inflammation. Large epidemiological studies have shown that OSA is more prevalent in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension than in the general population. Thus, elucidating the effects of OSA on adverse outcomes in patients with pulmonary hypertension is crucial in risk assessments and therapeutic recommendations for affected individuals. There is, however, insufficient evidence to determine whether OSA and associated physiological sequelae/phenotypes have a prognostic impact on these patients. The investigators propose a prospective, observational study to determine the impact of OSA and associated physiological parameters on clinical outcomes in patients with pulmonary hypertension. The prevalence, phenotypes, and predictors of OSA in the setting of pulmonary hypertension will also be investigated. Adult patients diagnosed with pulmonary hypertension by right heart catheterization are eligible. Recruited patients will undergo an overnight cardiorespiratory study using a Level III portable device before hospital discharge. The cardiorespiratory tracings during sleep will be analyzed and audited by a certified sleep physician. The patients will be divided into two groups based on the apnea-hypopnea index (AHI): OSA (AHI ≥ 5) and non-OSA (AHI\<5) groups. Hypoxemic parameters such as time percentage spent with oxygen saturation below 90% and nadir oxygen saturation were all collected. Baseline clinical characteristics, such as the Epworth sleepiness scales, were also obtained. The primary endpoint of this study was clinical worsening (CW), defined as the composite event of a reduction in exercise capacity (15% compared with the previous six-minute walk distance), worsening in World Health Organization functional class, non-elective hospitalization for pulmonary hypertension (need for an intravenous diuretic or inotropic drugs, new targeted therapies, lung transplantation, or septostomy), or all-cause mortality. Secondary endpoints include individual outcomes of clinical worsening and all-cause mortality.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
This study's planned enrollment of 480 is above the median of 105 across 668 observational studies indexed under Sleep Apnea, Obstructive.
Browse Sleep Apnea, Obstructive studies →Chinese Pulmonary Vascular Disease Research Group is the lead sponsor of 17 studies on the registry; 11 are open to participants now.
Compared within Sleep Apnea, Obstructive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sleep Apnea Syndromes. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Consecutive patients admitted to Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College diagnosed with pulmonary hypertension that meet inclusion and exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All subjects diagnosed with pulmonary hypertension by right heart catheterization agreeing to participate and meeting inclusion criteria but not meeting exclusion criteria
Diagnostic Test: Level III portable sleep study
Recruited patients will undergo an overnight cardiorespiratory study using a Level III portable device before hospital discharge
Clinical worsening
The composite event of a reduction in exercise capacity (15% compared with the previous six-minute walk distance), worsening in World Health Organization functional class, non-elective hospitalization for pulmonary hypertension (need for an intravenous diuretic or inotropic drugs, new targeted therapies, lung transplantation, or septostomy), or all-cause mortality.
Time frame: 1 year
Individual clinical worsening outcomes
Number of patients with reduction in exercise capacity, reduction in WHO functional classes, non-elective hospitalization for pulmonary hypertension and all-cause mortality.
Time frame: 1 year, 3 years and 5 years
Clinical worsening
The composite event of a reduction in exercise capacity (15% compared with the previous six-minute walk distance), worsening in World Health Organization functional class, non-elective hospitalization for pulmonary hypertension (need for an intravenous diuretic or inotropic drugs, new targeted therapies, lung transplantation, or septostomy), or all-cause mortality.
Time frame: 3 year, 5 years
All-cause mortality
All-cause mortality
Time frame: 1 year, 3 year, 5 years
Plan to share: Undecided
Started May 2020 (actual). Primary completion is estimated for Dec 2028, 103 months after the start.
Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 103 months is above that.
Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2025 → Dec 2028 and completion Dec 2025 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese Pulmonary Vascular Disease Research Group